Vascular Disease, Peripheral
12
1
1
5
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
8.3%
1 terminated out of 12 trials
83.3%
-3.2% vs benchmark
0%
0 trials in Phase 3/4
60%
3 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (12)
Brain Vascular and Neurocognitive Health
Immunomodulatory Effects of PCSK9 Inhibition
Correlating Multispectral Near-Infrared Imaging to Standard Vascular Diagnostics
Inter-individual Physiological Response to a Training and Detraining Period in Cardiometabolic Risk Factors Subjects
Disrupt PAD+ Study With the Shockwave Medical M5+ Peripheral IVL System
Heparin-Binding Protein and Heparins
Vascular Amputee Physical Performance Qualitative (VAmPP-Q) Study
Prevalence of the Appearance of Diabetic Ulcers in Patients With 3D Insole and LSCI.
Identification of Biomarkers for the Study of the Diabetic Foot and Evolution.
3 Month PHI PAD PoM Study
Prevention of Restenosis Following Revascularization
Pilot Study to Evaluate the Safety and Preliminary Efficacy of the Peritec Peritoneal Lined Stent and Delivery System